Effect of tolvaptan on renal handling of water and sodium, GFR and central hemodynamics in autosomal dominant polycystic kidney disease during inhibition of the nitric oxide system: a randomized, placebo-controlled, double blind, crossover study

BACKGROUND: Tolvaptan slows progression of autosomal dominant polycystic kidney disease (ADPKD) by antagonizing the vasopressin-cAMP axis. Nitric oxide (NO) stimulates natriuresis and diuresis, but its role is unknown during tolvaptan treatment in ADPKD. METHODS: Eighteen patients with ADPKD receive...

Descripción completa

Detalles Bibliográficos
Autores principales: Al Therwani, Safa, Malmberg, My Emma Sofie, Rosenbaek, Jeppe Bakkestroem, Bech, Jesper Noergaard, Pedersen, Erling Bjerregaard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5558668/
https://www.ncbi.nlm.nih.gov/pubmed/28810844
http://dx.doi.org/10.1186/s12882-017-0686-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5558668/
https://www.ncbi.nlm.nih.gov/pubmed/28810844
http://dx.doi.org/10.1186/s12882-017-0686-3

Ejemplares similares